Treatment of Chronic Hepatitis B in 2002

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F03%3A00007828" target="_blank" >RIV/65269705:_____/03:00007828 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of Chronic Hepatitis B in 2002

Popis výsledku v původním jazyce

Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches ha

Název v anglickém jazyce

Treatment of Chronic Hepatitis B in 2002

Popis výsledku anglicky

Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches ha

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NI7484" target="_blank" >NI7484: Závislost setrvalé virologické odpovědi na virové kinetice v počátcích léčby chronické hepatitidy C kombinací alfa-interferonu, nebo pegylovaného interferonu, a ribavirinu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2003

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislavské lekárské listy

ISSN

0006-9248

e-ISSN

—

Svazek periodika

104

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

5

Strana od-do

59-63

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—